Working… Menu

OPTION: A Trial to Assess the Safety & Efficacy of MS1819 in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis (OPTION)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03746483
Recruitment Status : Completed
First Posted : November 19, 2018
Last Update Posted : February 20, 2020
Information provided by (Responsible Party):
AzurRx BioPharma, Inc.

Brief Summary:
The primary objectives of this study are to assess the safety and efficacy of MS1819-SD vs porcine pancreatic enzyme replacement therapy (PERT) in patients with exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF).

Condition or disease Intervention/treatment Phase
Exocrine Pancreatic Insufficiency (EPI) Cystic Fibrosis (CF) Drug: MS1819-SD Drug: Porcine PERT Phase 2

Detailed Description:

This is a Phase 2, open-label, multi-center, 2x2 crossover study assessing the safety and efficacy of MS1819-SD vs porcine PERT given at the same dose that was being administered during the pre-study period.

MS1819-SD will be assessed in a 2x2 crossover including at least 30 patients completing both periods.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 32 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: 2x2 Crossover
Masking: None (Open Label)
Masking Description: Unblinded
Primary Purpose: Treatment
Official Title: A Phase 2, Open-Label, Multicenter, 2x2 Crossover Trial to Assess the Safety and Efficacy of MS1819-SD in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
Actual Study Start Date : January 10, 2019
Actual Primary Completion Date : July 13, 2019
Actual Study Completion Date : July 27, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cystic Fibrosis

Intervention Details:
  • Drug: MS1819-SD
    MS1819-SD, an oral, non-systemic, that is non-enterically-coated. It is a yeast-derived (non-porcine) lipase pancreatic enzyme replacement.
  • Drug: Porcine PERT
    Porcine PERT is being used as a comparator to MS1819-SD as a second drug/intervention

Primary Outcome Measures :
  1. Safety of MS1819-SD by number of subjects reporting 1 or more adverse events [ Time Frame: 6 weeks ]
    Number of subjects reporting 1 or more adverse events

  2. Efficacy of MS1819-SD: Coefficient of fat absorption (CFA) [ Time Frame: 6 weeks ]
    Coefficient of fat absorption (CFA)

Secondary Outcome Measures :
  1. Stool weights [ Time Frame: 6 weeks ]
    The relative efficacy of MS1819-SD compared to porcine PERT will be assessed using stool weights

  2. Signs and symptoms of malabsorption [ Time Frame: 6 weeks ]
    The relative efficacy of MS1819 compared to porcine PERT will be assessed using signs and symptoms of malabsorption

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Cystic fibrosis, based on 2 clinical features consistent with CF, plus initial diagnostic sweat chloride ≥ 60 mmol/L
  2. Under stable dose of porcine PERT
  3. A fair or better nutritional status
  4. Fecal elastase <100 µg/g
  5. Standard-of-care medications including CFTR modulators are allowed

Exclusion Criteria:

  1. History or diagnosis of fibrosing colonopathy
  2. Any chronic diarrheal illness unrelated to pancreatic insufficiency
  3. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level ≥5 ×upper limit of normal (ULN), or total bilirubin level ≥1.5 ×ULN at the Screening visit
  4. Feeding via an enteral tube during 6 months before screening
  5. Forced expiratory volume ≤30% at the Screening visit

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03746483

Layout table for location information
United States, California
Investigator Site 105
Long Beach, California, United States, 90806
United States, Florida
Investigator Site 102
Altamonte Springs, Florida, United States, 32701
Investigator Site 107
Miami, Florida, United States, 33136
United States, Illinois
Investigator Site 101
Glenview, Illinois, United States, 60025
United States, Kansas
Investigator Site 111
Wichita, Kansas, United States, 67214
United States, Maine
Investigator Site 108
Portland, Maine, United States, 04102
United States, Nevada
Investigator Site 103
Las Vegas, Nevada, United States, 89109
United States, Ohio
Investigator Site 110
Cleveland, Ohio, United States, 44106
Investigator Site 104
Toledo, Ohio, United States, 43606
United States, Pennsylvania
Investigator Site 106
Hershey, Pennsylvania, United States, 17033
United States, Texas
Investigator Site 109
Dallas, Texas, United States, 75235
Investigator Site 203
Karpacz, Poland
Investigator Site 202
Rabka-Zdrój, Poland
Investigator Site 204
Sopot, Poland
Sponsors and Collaborators
AzurRx BioPharma, Inc.
Layout table for additonal information
Responsible Party: AzurRx BioPharma, Inc. Identifier: NCT03746483    
Other Study ID Numbers: AZ-CF2001
First Posted: November 19, 2018    Key Record Dates
Last Update Posted: February 20, 2020
Last Verified: February 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by AzurRx BioPharma, Inc.:
Exocrine pancreatic insufficiency
Cystic Fibrosis
Pancreatic enzyme replacement therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Cystic Fibrosis
Exocrine Pancreatic Insufficiency
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases